[
Dyne Therapeutics Announces New Long-Term Clinical Data from Phase 1/2 DELIVER Trial of DYNE-251 in Duchenne Muscular Dystrophy Demonstrating Unprecedented and Sustained Functional Improvement Through
[og_img]
https://www.investing.com/news/press-releases/dyne-therapeutics-announces-new-longterm-clinical-data-from-phase-12-deliver-trial-of-dyne251-in-duchenne-muscular-dystrophy-demonstrating-unprecedented-and-sustained-functional-improvement-through-93CH-3930998
Investing.com
Dyne Therapeutics Announces New Long-Term Clinical Data from Phase 1/2 DELIVER Trial of DYNE-251 in Duchenne Muscular Dystrophy Demonstrating Unprecedented and Sustained Functional Improvement Through
Related articles